ATE359087T1 - Verwendung von erythropoietin zur behandlung oder vorbeugung von herzversagen - Google Patents

Verwendung von erythropoietin zur behandlung oder vorbeugung von herzversagen

Info

Publication number
ATE359087T1
ATE359087T1 AT03703525T AT03703525T ATE359087T1 AT E359087 T1 ATE359087 T1 AT E359087T1 AT 03703525 T AT03703525 T AT 03703525T AT 03703525 T AT03703525 T AT 03703525T AT E359087 T1 ATE359087 T1 AT E359087T1
Authority
AT
Austria
Prior art keywords
erythropoietin
treat
heart failure
prevent heart
suffering
Prior art date
Application number
AT03703525T
Other languages
English (en)
Inventor
Gilst Wiekert Hendrikus Van
Ronald Hendrik Peter Brus
Veldhuisen Dirk Jan Van
Robert Henk Henning
Boer Rudolf Allert De
Original Assignee
Crucell Holland Bv
Stichting Klinische Farmacolog
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crucell Holland Bv, Stichting Klinische Farmacolog filed Critical Crucell Holland Bv
Application granted granted Critical
Publication of ATE359087T1 publication Critical patent/ATE359087T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT03703525T 2002-01-09 2003-01-09 Verwendung von erythropoietin zur behandlung oder vorbeugung von herzversagen ATE359087T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NL0200010 2002-01-09

Publications (1)

Publication Number Publication Date
ATE359087T1 true ATE359087T1 (de) 2007-05-15

Family

ID=19760786

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03703525T ATE359087T1 (de) 2002-01-09 2003-01-09 Verwendung von erythropoietin zur behandlung oder vorbeugung von herzversagen

Country Status (8)

Country Link
US (1) US7335490B2 (de)
EP (1) EP1471930B1 (de)
CN (1) CN1612747A (de)
AT (1) ATE359087T1 (de)
AU (1) AU2003206251B2 (de)
CA (1) CA2476538C (de)
DE (1) DE60313125T2 (de)
WO (1) WO2003057242A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7297680B2 (en) * 1999-04-15 2007-11-20 Crucell Holland B.V. Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content
US7335490B2 (en) 2002-01-09 2008-02-26 Crucell Holland B.V. Use of erythropoietin for the preventive or curative treatment of cardiac failure
DE10219545A1 (de) * 2002-04-26 2003-11-06 Lang Florian Regulation der Apoptose
DE10234192B4 (de) 2002-07-26 2009-11-26 Epoplus Gmbh Co.Kg Verwendung von Erythropoetin
DE102004004509B4 (de) * 2004-01-23 2010-07-01 Epoplus Gmbh Co.Kg Einsatz von niedrig dosiertem Erythropoietin zur Stimulation endothelialer Vorläuferzellen sowie zur Organregeneration und Progressionsverlangsamung von Endorganschäden
US8067365B2 (en) * 2004-11-22 2011-11-29 University Of Utah Research Foundation Erythropoietin for treatment of multi-organ failure
DE102005003632A1 (de) 2005-01-20 2006-08-17 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Katheter für die transvaskuläre Implantation von Herzklappenprothesen
AR053416A1 (es) 2005-11-10 2007-05-09 Protech Pharma S A Combinacion de glicoisoformas para el tratamiento o prevencion de la septicemia, linea celular transgenica productora de glicoformas de eritropoyetina, composicion farmaceutica que comprende a dicha combinacion, procedimientos para obtener la linea celular, procedimiento para producir dicha combinac
US20070213813A1 (en) 2005-12-22 2007-09-13 Symetis Sa Stent-valves for valve replacement and associated methods and systems for surgery
US7896915B2 (en) 2007-04-13 2011-03-01 Jenavalve Technology, Inc. Medical device for treating a heart valve insufficiency
US9044318B2 (en) 2008-02-26 2015-06-02 Jenavalve Technology Gmbh Stent for the positioning and anchoring of a valvular prosthesis
BR112012021347A2 (pt) 2008-02-26 2019-09-24 Jenavalve Tecnology Inc stent para posicionamento e ancoragem de uma prótese valvular em um local de implantação no coração de um paciente
US20100261224A1 (en) * 2009-04-10 2010-10-14 Felsher Dean W Discovery and validation of cancer biomarkers using a protein analysis methodology to analyze specimens
US10856978B2 (en) 2010-05-20 2020-12-08 Jenavalve Technology, Inc. Catheter system
CA2799459A1 (en) 2010-05-25 2011-12-01 Jenavalve Technology Inc. Prosthetic heart valve and transcatheter delivered endoprosthesis comprising a prosthetic heart valve and a stent
WO2015028209A1 (en) 2013-08-30 2015-03-05 Jenavalve Technology Gmbh Radially collapsible frame for a prosthetic valve and method for manufacturing such a frame
EP4353203B1 (de) 2015-03-20 2026-08-19 JenaValve Technology, Inc. Herzklappenprotheseneinführungssystem
EP3632378B1 (de) 2015-05-01 2024-05-29 JenaValve Technology, Inc. Vorrichtung mit reduzierter herzschrittmacherrate bei herzklappenersatz
WO2017195125A1 (en) 2016-05-13 2017-11-16 Jenavalve Technology, Inc. Heart valve prosthesis delivery system and method for delivery of heart valve prosthesis with introducer sheath and loading system
EP3573579B1 (de) 2017-01-27 2023-12-20 JenaValve Technology, Inc. Herzklappennachahmung
CN106822903B (zh) * 2017-02-13 2019-07-23 牡丹江医学院 用于治疗心衰的药物组合物及其应用
WO2024102411A1 (en) 2022-11-09 2024-05-16 Jenavalve Technology, Inc. Catheter system for sequential deployment of an expandable implant

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5684016A (en) * 1984-04-12 1997-11-04 Hoechst Aktiengesellschaft Method of treating cardiac insufficiency
CA1332049C (en) * 1988-10-07 1994-09-20 Eli Lilly And Company Eukaryotic expression
ZA975264B (en) * 1996-06-17 1997-12-17 Smithkline Beecham Corp Method for treating congestive heart failure.
JP2002538202A (ja) * 1999-03-08 2002-11-12 メルク エンド カムパニー インコーポレーテッド HMG−CoAレダクターゼ阻害剤のジヒドロキシオープンアシッド及びその塩
TR200103785T2 (tr) * 1999-04-13 2002-06-21 The Kenneth S. Warren Institute, Inc. Uyarılabilir doku işlevinin periferik olarak uygulanan eritropoietin vasıtasıyla düzenlenmesi
ES2378272T3 (es) * 1999-04-15 2012-04-10 Crucell Holland B.V. Producción de proteína recombinante en una célula humana
DE60131393D1 (de) 2000-05-02 2007-12-27 Action Pharma As Verfahren zur behandlung von erkrankungen assoziiert mit akuten entzündung unter nichtischämischen zustände
US6531121B2 (en) * 2000-12-29 2003-03-11 The Kenneth S. Warren Institute, Inc. Protection and enhancement of erythropoietin-responsive cells, tissues and organs
US7335490B2 (en) 2002-01-09 2008-02-26 Crucell Holland B.V. Use of erythropoietin for the preventive or curative treatment of cardiac failure

Also Published As

Publication number Publication date
CA2476538C (en) 2012-07-17
AU2003206251B2 (en) 2008-03-13
AU2003206251A1 (en) 2003-07-24
EP1471930B1 (de) 2007-04-11
EP1471930A1 (de) 2004-11-03
DE60313125T2 (de) 2007-12-20
CA2476538A1 (en) 2003-07-17
US20050075287A1 (en) 2005-04-07
CN1612747A (zh) 2005-05-04
WO2003057242A1 (en) 2003-07-17
DE60313125D1 (de) 2007-05-24
US7335490B2 (en) 2008-02-26

Similar Documents

Publication Publication Date Title
DE60313125D1 (de) Verwendung von erythropoietin zur behandlung oder vorbeugung von herzversagen
EP4706638A3 (de) Verfahren zur behandlung von herzinsuffizienz durch verabreichung von omecamtiv mecarbil
NO20061325L (no) Kombinasjon av legemidler for behandling av neoplasmer
DE59907752D1 (de) Verwendung von erythropoietin oder erythropoietin-derivaten zur behandlung von cerebralen ischämien
SG149027A1 (en) Substituted urea derivatives for treating cardiac diseases
DE60113548D1 (de) Cyanomethyl-substituierte thiazolium- und imidazolium-verbindungen und behandlung von erkrankungen im zusammenhang mit proteinalterung
DE50310516D1 (de) Fredericamycin-derivate
DE502005010615D1 (de) Mittel zur behandlung von entzündlichen erkrankungen
WO2003092617A3 (en) Combinations for the treatment of inflammatory skin disorders
ATE525084T1 (de) Verwendung von mindestens einem botulinum- neurotoxin zur behandlung von schmerzen infolge therapeutischer behandlungen für das aids-virus
DE69840497D1 (de) Verwendung von Aplidine zur Behandlung von kardiovaskulären Erkrankungen
BRPI0415756A (pt) lipólise medicamentosa local, dirigida
ATE420099T1 (de) Medikament zur wachstumsinhibierung von tumoren
ATE429916T1 (de) Verwendung von sulfonamid-derivaten bei der behandlung von adipositas oder zur verringerung der nahrungsaufnahme
WO2004006849A3 (en) Combinations of drugs for the treatment of neoplasms
ATE522215T1 (de) Verwendung von 3,11b-cis-dihydrotetrabenazine zur behandlung von symptomen von huntington-chorea
CY1111353T1 (el) Χρηση ενωσεων κααλαλιδης για την παραγωγη φαρμακου για τη θεραπεια της ψωριασης
ATE553760T1 (de) Verwendung von alverin zur behandlung von hauterkrankungen
DE60200160D1 (de) Verwendung von Cilobradine oder pharmazeutisch akzeptablen Salze zur Behandlung oder Prävention von Herzversagen
DE60326742D1 (de) Piperazin und piperadin-derivate für die behandlung von neurologischen krankheiten
ATE206052T1 (de) Verwendung von sphingosin-1-phosphat, sphingosin- 1-phosphat-derivaten und/oder deren gemische zur behandlung von entzündlichen hautkrankheiten
EP4324522A3 (de) Verfahren zur behandlung von nierenfunktionsbeeinträchtigten fabry-patienten
ATE314066T1 (de) Verwendung von buprenorphin zur therapie der harninkontinenz
ATE239492T1 (de) Verwendung von einem bpi protein zur herstellung eines medikamentes zur behandlung von chronischen herzerkrankungen
ATE337004T1 (de) Verwendung von mangafodipir zur behandlung der hepatozellularen insuffizienz

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties